Manon Reda
Overview
Explore the profile of Manon Reda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
38
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ladoire S, Kamga A, Galland L, Reda M, Desmoulins I, Mayeur D, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):10.
PMID: 39893163
Adjuvant CDK4/6 inhibitors (abemaciclib and ribociclib) associated with endocrine therapy reduced the risk of relapse for HR+/HER2- early breast cancer (eBC) patients in the monarchE and NATALEE trials. In this...
2.
Ladoire S, Kamga A, Galland L, Desmoulins I, Mayeur D, Kaderbhai C, et al.
Breast
. 2024 Sep;
78:103789.
PMID: 39243563
Background: The results of the OlympiA study led to the approval of a PARP inhibitor (olaparib) as adjuvant treatment for early breast cancer (eBC) at high risk of relapse in...
3.
Sewani S, Azamian M, Mendelsohn B, Mau-Them F, Reda M, Nambot S, et al.
Am J Med Genet A
. 2023 Oct;
194(3):e63445.
PMID: 37872713
The bromodomain adjacent to zinc finger 2B (BAZ2B) gene encodes a chromatin remodeling protein that has been shown to perform a variety of regulatory functions. It has been proposed that...
4.
Mazel B, Bertolone G, Baurand A, Cosset E, Sawka C, Robert M, et al.
Cancer Med
. 2023 Sep;
12(18):18786-18796.
PMID: 37694493
Introduction: With the emergence of targeted therapies, there is a need to accurately identify more tumor biomarkers. The EXOMA trial was designed to offer tumor and germline exome sequencing (ES)...
5.
Faivre L, Crepin J, Reda M, Nambot S, Carmignac V, Abadie C, et al.
Clin Genet
. 2023 Aug;
104(5):554-563.
PMID: 37580112
The PIK3CA-related overgrowth spectrum (PROS) encompasses various conditions caused by mosaic activating PIK3CA variants. PIK3CA somatic variants are also involved in various cancer types. Some generalized overgrowth syndromes are associated...
6.
Galland L, Roussot N, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831640
Breast cancer is the most frequently occurring cancer worldwide. With its increasing incidence, it is a major public health problem, with many therapeutic challenges such as precision medicine for personalized...
7.
Reda M, Fouquier A, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, et al.
Breast
. 2023 Feb;
68:149-156.
PMID: 36773403
Background: Taxanes are major drugs for metastatic breast cancer (MBC) treatment, and are generally well tolerated, making them attractive for therapeutic reintroduction (rechallenge) during metastatic course. In view of the...
8.
Verdez S, Albuisson J, Duffourd Y, Boidot R, Reda M, Thauvin-Robinet C, et al.
Pharmacogenomics
. 2022 Aug;
23(14):759-770.
PMID: 36043386
Germline sequencing of individual genomes can detect alleles responsible for adverse drug reactions (ADRs) in relation to chemotherapy, targeted agents, antiemetics or pain treatment. To evaluate the interest of such...
9.
Reda M, Macaire P, Bellio H, Uwer L, Ilie S, Lorgis V, et al.
Cancer Chemother Pharmacol
. 2022 Jan;
89(2):197-208.
PMID: 34997290
Background: Granulocyte colony-stimulating factors (G-CSF) are commonly given to limit chemotherapy-induced neutropenia, but, in case of weekly chemotherapy such as eribulin, their administration schedules remain empirical. Objectives: This pharmacokinetic/pharmacodynamic (PK/PD)...
10.
Reda M, Richard C, Bertaut A, Niogret J, Collot T, Fumet J, et al.
EBioMedicine
. 2020 Jan;
51:102624.
PMID: 31923800
Background: Genomically-guided clinical trials are performed across different tumor types sharing genetic mutations, but trial organization remains complex. Here we address the feasibility and utility of routine somatic and constitutional...